Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00425555 |
This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.
Condition | Intervention | Phase |
---|---|---|
Cutaneous T-Cell Lymphoma |
Drug: LBH589 |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma |
Estimated Enrollment: | 118 |
Study Start Date: | December 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria
Exclusion criteria
Contact: Novartis | 862 778 8300 |
Study Chair: | Novartis | Novartis |
Study ID Numbers: | CLBH589B2201 |
Study First Received: | January 22, 2007 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00425555 |
Health Authority: | United States: Food and Drug Administration |
Cutaneous T-Cell Lymphoma, adults Mycosis Fungoides Sézary Syndrome CTCL |
Lymphatic Diseases Mycoses Sezary syndrome Immunoproliferative Disorders Cutaneous T-cell lymphoma Lymphoma, T-Cell |
Sezary Syndrome Mycosis Fungoides Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma Lymphoma, T-Cell, Cutaneous |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |